KCM
TVTX icon

Kynam Capital Management’s Travere Therapeutics TVTX Stock Holding History

Kynam Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63M Buy
+54,900
New +$1.64M 0.1% 38

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kynam Capital Management's TVTX Position: Q1 2026 in Review

Kynam Capital Management increased its Travere Therapeutics (TVTX) stake by 203% in Q1 2026, buying an estimated $31.4M and bringing the position to 1,569,018 shares worth $46.6M. The position accounts for 2.88% of the portfolio, ranked #9.

Kynam Capital Management first reported a position in TVTX in Q4 2021 and has held it in 18 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Kynam Capital Management held 1,569,018 shares of Travere Therapeutics worth $46.6M as of Q1 2026.
  • Kynam Capital Management bought 1,051,134 Travere Therapeutics shares in Q1 2026, an estimated $31.4M.
  • Travere Therapeutics made up 2.88% of Kynam Capital Management's portfolio in Q1 2026, its #9 holding.
  • Kynam Capital Management first reported a position in Travere Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.